01 Increased Use of Minimally Invasive TechniquesThe global market for inflation devices is growing due to the rising popularity of minimally invasive surgical procedures. Since its introduction in the late 1990s, minimally invasive surgical procedures such as laparoscopy, anti-reflux surgery, and colectomy have become increasingly common. As opposed to open surgeries, minimally invasive techniques offer numerous benefits. These procedures result in less noticeable scars since they require smaller incisions. Additionally, these techniques result in reduced discomfort and bleeding. These procedures' success rate is also higher than typical open surgeries. Therefore, both patients and doctors favor these procedures. Balloons are also used in minimally invasive surgeries, including balloon sinuplasty and minimally invasive heart valve surgery.
02 Growing Global Geriatric PopulationOne of the key factors propelling the market for inflation devices is the sharp increase in the elderly population. The number of older adults worldwide has substantially increased, making them more susceptible to numerous diseases like lung, bladder, kidney, and melanoma. According to data from the U.S. Census Bureau, the old population in the United States comprised 14.9% of the overall population in 2015, or 47.8 million people. It is predicted that this figure will rise to 78.0 million by 2035. The increase in the global geriatric population over the next 35 years is seen above. These folks are more prone to certain illnesses that need surgical intervention. For instance, cardiovascular diseases are very common in the older population. Similarly, geriatric patients are predisposed to gastroenterological diseases, which require procedures including inflating devices and spur global market expansion.
01 Expensive Surgical ProceduresThe majority of surgical procedures are very expensive. Like for example, the use of inflating devices is necessary during expensive heart operations, including the use of balloons and stents. These cardiac treatments' high cost is expected to negatively impact the market's potential over the next several years. Product recalls are predicted to continue to be a substantial roadblock to the shipment of inflation devices through 2030. For instance, Atrium Medical Corp., a division of Getinge, a leading medical technology provider, announced the recall of their iCast Covered Stent System in June 2022.Additionally, issues with balloons used in endovascular procedures quickly deflating gave rise to the recall. The U.S. National Library of Medicine estimates that the average price of cardiac surgery is USD 53,707. This does not include the fee for the balloon used in the treatment. Likewise, the average cost of an endoscopy to check for gastroenterological problems is USD 2,750. The high cost of surgeries prevents more people from using inflating devices and slows the market's expansion.
01 High Potential for Expansion in Emerging MarketsFor manufacturers of inflation-controlling devices, emerging markets present a lucrative potential for corporate growth. The dynamic life sciences sector also fueled the market expansion in developing nations like China and India. Another factor driving the expansion of this market is the worldwide increase in healthcare spending. Additionally, expanding the healthcare industry in developing nations is anticipated to support market expansion. Developing nations in the Asia-Pacific and LAMEA region have a sizable patient pool suffering from cardiovascular problems and high market potential. Therefore, the aspects above present lucrative prospects for market expansion during the forecast period.
May 2026 Corvention received U.S. FDA 510(k) clearance for the KardiaPsi Balloon Catheter, engineered for ultrahigh-pressure inflation during treatment of heavily calcified lesions and designed for rapid inflation and deflation using a single inflation device.
July 2025 Teleflex completed the EUR 760 million acquisition of BIOTRONIK's Vascular Intervention business, adding balloon catheters and other coronary and peripheral interventional devices to its portfolio.